{"url_path":"/sec/acrv/8-k/2026-06-17/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-17","source_url":"https://www.sec.gov/Archives/edgar/data/1781174/0001193125-26-274410-index.html","accession_number":"0001193125-26-274410","cik":"0001781174","ticker":"ACRV","issuer_name":"Acrivon Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1781174/0001193125-26-274410-index.html","primary_entity_key":"0001781174","primary_entity_name":"Acrivon Therapeutics, Inc."},"word_count":246,"has_tables":true,"body_markdown":"## Item 5.07 Submission of Matters to a Vote of Security Holders.\n\n##  \n\nAt the Annual Meeting, a quorum of 31,336,993.43 shares of the Company’s common stock, or 73.21% of the outstanding shares of common stock entitled to vote as of the record date of April 23, 2026, were present or represented by proxy.\n\nThree items of business were acted upon by the stockholders at the Annual Meeting. The final results for the votes regarding each proposal are set forth below.\n\n \n\nProposal One: Election of Michael Tomsicek, M.B.A. and Charles Baum, M.D., Ph.D. as Class I Directors.\n\n \n\nMichael Tomsicek, M.B.A. and Charles Baum, M.D., Ph.D. were each elected to serve as a Class I director to hold office until the Company’s 2029 Annual Meeting of Stockholders and until the election and qualification of his successor. Votes were cast as follows:\n\n \n\n \n\nFor\n\nWithheld\n\nBroker Non-Votes\n\nMichael Tomsicek, M.B.A.\n\n24,020,408\n\n1,229,385\n\n6,087,200\n\nCharles Baum, M.D., Ph.D.\n\n23,657,074\n\n1,592,719\n\n6,087,200\n\n \n\nProposal Two: Ratification of Appointment of Independent Registered Public Accounting Firm.\n\nThe stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 by the following vote:\n\n \n\nFor\n\nAgainst\n\nAbstain\n\nBroker Non-Votes\n\n31,278,962\n\n53,857\n\n4,174\n\n0\n\nProposal Three: Approval of the Amendment and Restatement of the Company’s 2022 Equity Incentive Plan.\n\n \n\nThe stockholders approved the Acrivon Therapeutics, Inc. Amended and Restated 2022 Equity Incentive Plan. Votes were cast as follows:\n\n \n\nFor\n\nAgainst\n\nAbstain\n\nBroker Non-Votes\n\n20,546,400\n\n3,757,400\n\n104,757\n\n6,928,436"}